244 related articles for article (PubMed ID: 38148074)
1. Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era.
Nishikawa H; Kim SK; Asai A
In Vivo; 2024; 38(1):40-47. PubMed ID: 38148074
[TBL] [Abstract][Full Text] [Related]
2. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
4. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
6. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
[TBL] [Abstract][Full Text] [Related]
7. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
8. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients.
Okumura T; Joshita S; Iwadare T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Kimura T; Umemura T
J Viral Hepat; 2023 Sep; 30(9):731-739. PubMed ID: 37363934
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs].
Gao TJ; Han GY; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):905-909. PubMed ID: 31941249
[TBL] [Abstract][Full Text] [Related]
11. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
12. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine.
Colombatto P; Coco B; Bonino F; Brunetto MR
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458431
[TBL] [Abstract][Full Text] [Related]
13. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
14. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
16. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Hall S; Howell J; Visvanathan K; Thompson A
Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335
[TBL] [Abstract][Full Text] [Related]
17. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
18. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
Wu JW; Kao JH; Tseng TC
Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
[TBL] [Abstract][Full Text] [Related]
19. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.
Haga H; Saito T; Okumoto K; Tomita K; Katsumi T; Mizuno K; Nishina T; Watanabe H; Ueno Y
J Viral Hepat; 2019 Jul; 26(7):866-872. PubMed ID: 30924226
[TBL] [Abstract][Full Text] [Related]
20. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
